1. Home
  2. BLKB vs GH Comparison

BLKB vs GH Comparison

Compare BLKB & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackbaud Inc.

BLKB

Blackbaud Inc.

HOLD

Current Price

$64.28

Market Cap

2.7B

Sector

Technology

ML Signal

HOLD

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$103.37

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLKB
GH
Founded
1981
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
14.1B
IPO Year
2004
2018

Fundamental Metrics

Financial Performance
Metric
BLKB
GH
Price
$64.28
$103.37
Analyst Decision
Hold
Strong Buy
Analyst Count
2
21
Target Price
$70.50
$96.48
AVG Volume (30 Days)
341.2K
1.8M
Earning Date
10-29-2025
10-29-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,136,093,000.00
$902,569,000.00
Revenue This Year
N/A
$35.00
Revenue Next Year
$4.00
$26.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.38
52 Week Low
$54.56
$29.91
52 Week High
$81.39
$112.43

Technical Indicators

Market Signals
Indicator
BLKB
GH
Relative Strength Index (RSI) 60.19 57.55
Support Level $62.57 $96.28
Resistance Level $64.84 $103.17
Average True Range (ATR) 1.72 3.53
MACD 0.21 -0.70
Stochastic Oscillator 84.38 71.98

Price Performance

Historical Comparison
BLKB
GH

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Share on Social Networks: